PMID- 31086250 OWN - NLM STAT- MEDLINE DCOM- 20201104 LR - 20210109 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 9 IP - 1 DP - 2019 May 13 TI - Effects of diaphragmatic myofascial release on gastroesophageal reflux disease: a preliminary randomized controlled trial. PG - 7273 LID - 10.1038/s41598-019-43799-y [doi] LID - 7273 AB - The purpose of this study is to investigate whether implementing a myofascial release (MFR) protocol designed to restore the myofascial properties of the diaphragm has any effect on the symptoms, quality of life, and consumption of proton pump inhibitors (PPI) drugs by patients with non-erosive gastroesophageal reflux disease (GERD). We randomized 30 patients with GERD into a MFR group or a sham group. Changes in symptomatology and quality of life were measured with the Reflux Disease Questionnaire and the Gastrointestinal Quality of Life Index. Need of PPIs was measured as the milligrams of drug intake over the 7 days prior to each assessment. All variables were assessed at baseline, one week and 4 weeks after the end of the treatment. At week 4, patients receiving MFR showed significant improvements in symptomatology (mean difference-1.1; 95% CI: -1.7 to -0.5), gastrointestinal quality of life (mean difference 18.1; 95% CI: 4.8 to 31.5), and PPIs use (mean difference-97 mg; 95% CI: -162 to -32), compared to the sham group. These preliminary findings indicate that the application of the MFR protocol we used in this study decreased the symptoms and PPIs usage and increased the quality of life of patients with non-erosive GERD up to four weeks after the end of the treatment. FAU - Martinez-Hurtado, I AU - Martinez-Hurtado I AD - Department of Physiotherapy, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. FAU - Arguisuelas, M D AU - Arguisuelas MD AD - Department of Physiotherapy, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. FAU - Almela-Notari, P AU - Almela-Notari P AD - Department of Gastroenterology, Hospital General de Castellon, Castellon, Spain. AD - Department of Medicine, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. FAU - Cortes, X AU - Cortes X AD - Department of Medicine, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. AD - Digestive Disease Department, Hospital of Sagunto, Valencia, Spain. FAU - Barrasa-Shaw, A AU - Barrasa-Shaw A AD - Department of Surgery, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. AD - Hospitales Vithas Nisa Virgen del Consuelo & 9 de Octubre, Valencia, Spain. FAU - Campos-Gonzalez, J C AU - Campos-Gonzalez JC AD - Department of Medicine, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. AD - Hospital Arnau de Vilanova, Valencia, Spain. FAU - Lison, J F AU - Lison JF AD - Department of Medicine, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain. juanfran@uchceu.es. AD - CIBER of Physiopathology of Obesity and Nutrition CIBERobn, CB06/03 Carlos III Health Institute, Madrid, Spain. juanfran@uchceu.es. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20190513 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Proton Pump Inhibitors) SB - IM MH - *Diaphragm MH - Female MH - Gastroesophageal Reflux/drug therapy/*therapy MH - Humans MH - Male MH - Massage/*methods MH - Proton Pump Inhibitors/therapeutic use MH - Quality of Life MH - Surveys and Questionnaires MH - Treatment Outcome PMC - PMC6513998 COIS- The authors declare no competing interests. EDAT- 2019/05/16 06:00 MHDA- 2020/11/05 06:00 PMCR- 2019/05/13 CRDT- 2019/05/16 06:00 PHST- 2019/01/28 00:00 [received] PHST- 2019/04/29 00:00 [accepted] PHST- 2019/05/16 06:00 [entrez] PHST- 2019/05/16 06:00 [pubmed] PHST- 2020/11/05 06:00 [medline] PHST- 2019/05/13 00:00 [pmc-release] AID - 10.1038/s41598-019-43799-y [pii] AID - 43799 [pii] AID - 10.1038/s41598-019-43799-y [doi] PST - epublish SO - Sci Rep. 2019 May 13;9(1):7273. doi: 10.1038/s41598-019-43799-y.